Pep IQ
← Pep IQ
Substantial preclinical foundation. VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide isolated from porcine small intestine in 1970 by Sami Said and Viktor Mutt. Despite the name, VIP is widely distributed throughout the body — central and peripheral nervous systems, GI tract, lungs, heart, and immune system. Functions as a neurotransmitter, neuromodulator, and immunoregulatory peptide. Mechanism: G-protein-coupled receptor agonism at VPAC1 (immune system, lungs, liver) and VPAC2 (CNS, smooth muscle, immune cells). Anti-inflammatory across multiple organ systems. Animal studies — Delgado, Gomariz et al. — demonstrated VIP administration significantly reduced incidence and severity of arthritis in experimental models, completely abrogating joint swelling and cartilage/bone destruction. Pubmed 23444784 — rat work showed intranasal VIP 200 µg/mL improved spatial memory in Aβ25-35 Alzheimer's model with minor self-resolving nasal mucosa irritation as toxicity finding.
Two distinct frameworks. Shoemaker CIRS protocol — the dominant clinical context: 50 mcg per spray intranasal, 4× daily (200 mcg/day total), used as the FINAL step after completing prior protocol stages (mycotoxin clearance, MARCoNS treatment, etc.). Using VIP before clearing ongoing biotoxin exposure is considered counterproductive and may worsen symptoms — sequence matters. Extended grey-matter restoration protocol uses 6–8 sprays/day (300–400 mcg/day) for 12+ weeks. Compounded as prescription nasal spray. Outside CIRS — broader neurological and anti-inflammatory community use is much less standardised: 0.2 mg (200 mcg) daily intranasal titrated per response is a typical starting framework. Side-effect profile: nasal irritation/congestion (intranasal), hypotension at higher doses (VIP is a vasodilator — those with low BP should start low).
Substantial Shoemaker observational evidence; limited rigorous external trials. Shoemaker et al. 2013 — intranasal VIP at 50 mcg 4× daily for 30 days in CIRS patients (after completing prior protocol steps): significant reduction in C4a and TGF-β1, quality-of-life improvement, restored estradiol and testosterone. Shoemaker et al. 2017 (Internal Medicine Review) — landmark grey matter restoration paper: extended VIP at 6–8 sprays/day for 12+ weeks safely restored grey matter volume in multiple brain nuclei in CIRS patients on NeuroQuant imaging. Over 10,000 patients treated in the Shoemaker series with 'unmatched safety' according to the survivingmold.com clinical record. Pulmonary hypertension trial — Petkov et al. 2003 — inhaled VIP reduced mean pulmonary artery pressure 10–15%, increased cardiac output, improved oxygen saturation in 8 patients. Aviptadil (synthetic VIP, RLF-100) studied in COVID-19-related ARDS trials with mixed results. Important caveat: CIRS itself remains a controversial diagnosis — not recognised by mainstream medicine in the same form Shoemaker describes — which colours the interpretive frame for VIP's primary use case.
Not FDA-approved for any indication. Compounded availability is shifting — the FDA announced plans to remove VIP from the list of drugs that may be compounded by licensed pharmacies in the United States, which has triggered patient advocacy responses (the 'Save VIP' campaign through survivingmold.com). Aviptadil (RLF-100, synthetic VIP) is in clinical development. EU and other markets generally do not have established VIP products — Shoemaker-protocol practitioners use compounding routes. Mechanistically novel — VIP/VPAC2 receptor work has therapeutic interest in type 2 diabetes (Hou et al. 2022, Front Endocrinol) and neuroinflammation.
VIP has substantial clinical use within a specific framework — the Shoemaker CIRS protocol's >10,000 patient clinical record, 2013 biomarker-normalisation data, and the 2017 grey-matter-restoration paper represent more documented human use than most research peptides receive. But three caveats matter: (1) the primary clinical context is CIRS, a diagnosis not accepted in the same form by mainstream medicine; (2) the grey-matter paper appeared in Internal Medicine Review rather than a high-impact journal, reflecting publication-venue choices that affect external validation; (3) outside CIRS, rigorous trial evidence is much thinner. Standard CIRS protocol: 50 mcg intranasal 4× daily after completing prior protocol steps; extended protocol 6–8 sprays/day for 12+ weeks. Pep IQ flags this honestly: members considering VIP for CIRS should work with a physician familiar with the Shoemaker protocol — sequence and prior steps genuinely matter. Members considering VIP for general anti-inflammatory or neurological purposes outside CIRS are extrapolating from a clinical framework whose dose-rationale was developed for a specific condition; the broader use case has thinner evidence support.
VIP — Vasoactive Intestinal Peptide — was discovered in 1969 by Sami Said and Viktor Mutt, who isolated it from porcine lung and intestinal tissue and observed that it dilated blood vessels. The name stuck. It is now one of the least accurate names in the entire field of peptide biology.
VIP is expressed throughout the central nervous system, enteric nervous system, thymus, lung tissue, and immune organs. It is produced by neurons, epithelial cells, and immune cells. It belongs to the secretin-glucagon superfamily alongside PACAP (pituitary adenylate cyclase-activating peptide), sharing structural homology that hints at deep evolutionary conservation — VIP sequences are highly similar across animals from fish to humans, suggesting the molecule is performing something fundamentally important.
The modern understanding of VIP is as an immune tolerance orchestrator: it programs dendritic cells to generate regulatory T cells rather than inflammatory ones, shifts macrophages from inflammatory to reparative states, maintains gut barrier integrity, and synchronises circadian clocks across the nervous system. The vasodilator identity that gave it its name is real but peripheral to its actual significance.
Why the name is misleading: VIP was named for its vasodilatory effects observed in the first isolation experiments in 1969. Subsequent decades of research revealed that vasodilation is probably the least important thing VIP does. It operates as a master immune tolerance signal — the key difference between "fire extinguisher" (VPAC1 — acute anti-inflammation) and "architect" (VPAC2 — long-term tolerance programming). The naming conventions of endocrinology freeze to the first observed function, regardless of what the molecule is actually for.
VIP's mechanism is defined by its two receptor subtypes, which serve fundamentally different functions and express at different times during immune activation. Understanding this distinction explains why VIP is being studied for chronic inflammatory conditions rather than just acute inflammation.